The use of aflibercept in ophthalmology: a review of randomized controlled trials
Journal
Annals of Eye Science
Journal Volume
2
Start Page
Article number 12
ISSN
2520-4122
Date Issued
2017-03
Author(s)
Abstract
Abstract: We reviewed randomized controlled trials associated with the intravitreal use of aflibercept for this article. These studies proved that aflibercept is an effective anti-vascular endothelial growth factor agent for the treatment of neovascular age-related macular degeneration (nAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), and macular edema associated with retinal vein occlusion. The incidence of severe ocular or systemic complications after intravitreal administration of aflibercept was low.
SDGs
Publisher
AME Publishing Company
Type
journal article